KRAS and neoplasm: To explore the potential predictive value of KRAS in immune checkpoint inhibitors (ICI), Liu conducted a heterogeneous pooled analysis of 23 studies and 5326 patients, which showed that KRAS-mutated tumors were more likely to be programmed death-ligand 1 (PD-L1)-positive (p = 0.037) and have a higher tumor mutational burden (TMB) status than KRAS WT tumors (p = 0.0002) [51].